beta
/Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
Abstract

Abstract N/A

RelatedView All
Authors 20View All
CitationsView All
Citing24
Cited By-